Canada’s Drug Agency Launches Consultation on New Methods Guide for Health Technology Assessments

By João L. Carapinha

December 2, 2024

Canada’s Drug Agency launched a consultation on their first-ever methods guide. This methods guide is designed to describe the processes involved in conducting health technology assessments (HTAs) and appraising the clinical evidence for drugs submitted to the Drug Reimbursement Review program.

Purpose and Scope

The methods guide aims to clarify the procedures that the agency follows. It details how evidence is evaluated in relation to HTAs for drug reimbursement.

Consultation Details

The consultation period is open from November 28, 2024, to January 28, 2025. This 8-week timeframe allows for feedback from interested parties, including those who generate and submit evidence, as well as those who conduct the evidence appraisal.

Content of the Methods Guide

This guide incorporates leading methodological practices from HTA organizations both within Canada and internationally. It includes the evaluation of clinical and economic evidence, patient and clinician input, and ethical and implementation considerations.

Objectives

The primary goal of the methods guide is to enhance transparency in the agency’s processes and provide a clearer understanding of their work. The agency intends this to be a living document and will update it periodically based on scientific advancements and user feedback.

Application and Use

The methods guide is part of a suite of drug review guidance documents, which also includes:
– Guidelines for the Economic Evaluation of Health Technologies: Canada
– Guidance for Reporting Real-World Evidence.

Stakeholder Engagement

The consultation seeks extensive feedback from partners and interested parties to improve the methods guide. Partners and interested parties can submit feedback by downloading the draft document, completing the feedback form, and sending it to the specified email address by January 28, 2025.

Role in Drug Reimbursement

The HTA process conducted by Canada’s Drug Agency is critical for informing decisions about drug reimbursement and implementation. The agency’s expert committees utilize these evaluations to make recommendations to public drug programs and cancer agencies (excluding Quebec).

In summary, the consultation on the methods guide represents a significant effort by Canada’s Drug Agency to enhance transparency, incorporate best practices, and ensure that their evaluation processes for drug reimbursement are robust and evidence-based.

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.